Cencora — Feb 2, 2026 release

FIRST QUARTER RESULTS Revenue of $85.9 billion for the First Quarter, a 5.5% Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.87 and Adjusted Diluted EPS of $4.08 Adjusted Operating Income Guidance Raised to Growth of 11.5% to 13.5% Adjusted Diluted EPS Guidance Range Reaffirmed at $17.45 to $17.75 for Fiscal 2026 Company Completes Acquisition of OneOncology   CONSHOHOCKEN, PA, February 4, 2026 - Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 9.4 percent to $4.08 in the fiscal first quarter from $3.73 in the prior year first quarter. Cencora is updating its outlook for fiscal year 2026. The Company does not provide forward-looking guidance on a GAAP basis as discussed below in Fiscal Year 2026 Expectations. Adjusted operating income guidance has been raised from the previous range of growth of 8% to 10% to growth of 11.5% to 13.5% primarily to reflect the completion of the acquisition of OneOncology and the performance of the U.S. Healthcare Solutions segment. “Cencora began fiscal 2026 by